These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38508535)

  • 1. Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin.
    van Os W; Pham AD; Eberl S; Minichmayr IK; van Hasselt JGC; Zeitlinger M
    Int J Antimicrob Agents; 2024 May; 63(5):107148. PubMed ID: 38508535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW; Craig WA; Andes D
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
    Vidaillac C; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
    Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
    J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
    Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Bowker KE
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
    van Os W; Zeitlinger M
    J Antimicrob Chemother; 2024 Feb; 79(2):443-446. PubMed ID: 38174805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations.
    Martins FS; Martins JES; Severino P; Annaert P; Sy SKB
    Br J Clin Pharmacol; 2023 Sep; 89(9):2726-2738. PubMed ID: 37005335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae.
    Wicha WW; Strickmann DB; Paukner S
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii11-iii18. PubMed ID: 30949707
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
    Urbán E; Stone GG
    Clin Microbiol Infect; 2019 Nov; 25(11):1429.e1-1429.e4. PubMed ID: 30980925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
    Andrey DO; François P; Manzano C; Bonetti EJ; Harbarth S; Schrenzel J; Kelley WL; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):343-350. PubMed ID: 27744604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
    Werth BJ; Steed ME; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.